Inhibitory efficacy of hypoxia-inducible factor 1α short hairpin RNA plasmid DNA-loaded poly (D, L-lactide-co-glycolide) nanoparticles on choroidal neovascularization in a laser-induced rat model

Gene Therapy

Volumn 17, Issue 3, 2010, Pages 338-351

  Zhang, C ^a   Wang, Y S ^a   Wu, H ^a   Zhang, Z X ^a   Cai, Y ^a   Hou, H Y ^a   Zhao, W ^a   Yang, X M ^a   Ma, J X ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Hypoxia inducible factor 1 ; L lactic glycolic acid) nanoparticles; Plasmid DNA; Poly (D; RNA interference

Indexed keywords

GREEN FLUORESCENT PROTEIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; NANOPARTICLE; PHOSPHATE BUFFERED SALINE; PLASMID DNA; POLYGLACTIN; SHORT HAIRPIN RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG RELEASE; DRUG TARGETING; GENE EXPRESSION; HISTOPATHOLOGY; NANOENCAPSULATION; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; NUCLEOTIDE SEQUENCE; PIGMENT EPITHELIUM; PRIORITY JOURNAL; RAT; RNA INTERFERENCE; SUBRETINAL NEOVASCULARIZATION;

ANIMALS; CHOROIDAL NEOVASCULARIZATION; GENE THERAPY; GENE TRANSFER TECHNIQUES; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; NANOPARTICLES; PLASMIDS; POLYGLACTIN 910; RATS; RATS, INBRED BN; RNA, SMALL INTERFERING;

RATTUS;

EID: 77949423366     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2009.158     Document Type: Article

References (79)

1. Hyman LG, Lilienfeld AM, Ferris III FL, Fine SL. Senile macular degeneration: a case-control study. Am J Epidemiol 1983; 118: 213-227.
2. Macular Photocoagulation Study G. Argon laser photocoagula-tion for neovascular maculopathy: five-year results from randomized clinical trials. Arch Ophthalmol 1991; 109: 1109-1114.
3. Treatment of Age-Related Macular Degeneration with Photo-dynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials\TAP report. Arch Ophthalmol 1999; 117: 1329-1345.
4. Grossniklaus HE, Ling JX, Wallace TM, Dithmar S, Lawson DH, Cohen C et al. Macrophage and retinal pigment epithelium expression of angiogenic cytokines in choroidal neovasculariza-tion. Mol Vis 2002; 8: 119-126.
5. Sheridan CM, Rice D, Hiscott PS, Wong D, Kent DL. The presence of AC133-positive cells suggests a possible role of endothelial progenitor cells in the formation of choroidal neovascularization. Invest Ophthalmol Vis Sci 2006; 47: 1642-1645.
6. Kent D, Sheridan C. Choroidal neovascularization: a wound healing perspective. Mol Vis 2003; 9: 747-755.
7. Otani A, Takagi H, Oh H, Koyama S, Ogura Y, Matumura M et al. Vascular endothelial growth factor family and receptor expression in human choroidal neovascular membranes. Microvasc Res 2002; 64: 162-169.
8. Ferrara N, Damico L, Shams N, Lowman H, Kim R. Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina 2006; 26: 859-870.
9. Kinose F, Roscilli G, Lamartina S, Anderson KD, Bonelli F, Spence SG et al. Inhibition of retinal and choroidal neovascular-ization by a novel KDR kinase inhibitor. Mol Vis 2005; 11: 366-373.
10. Aiello LP. Angiogenic pathways in diabetic retinopathy. N Engl J Med 2005; 353: 839-841.
11. Schwesinger C, Yee C, Rohan RM, Joussen AM, Fernandez A, Meyer TN et al. Intrachoroidal neovascularization in transgenic mice overexpressing vascular endothelial growth factor in the retinal pigment epithelium. Am J Pathol 2001; 158: 1161-1172.
12. Song SJ, Chung H, Yu HG. Inhibitory effect of YC-1, 3-(5-hydroxymethyl-2- furyl)-1-benzylindazole, on experimental choroidal neovascularization in rat. Ophthalmic Res 2008; 40: 35-40.
13. Ceradini DJ, Kulkarni AR, Callaghan MJ, Tepper OM, Bastidas N, Kleinman ME et al. Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat Med 2004; 10: 858-864.
14. Arjamaa O, Nikinmaa M, Salminen A, Kaarniranta K. Regulatory role of HIF-1a in the pathogenesis of age-related macular degeneration (AMD). Ageing Res Rev 2009; 8: 349-358.
15. Birch DG, Liang FQ. Age-related macular degeneration: a target for nanotechnology derived medicines. Int J Nanomedicine 2007; 2: 65-77.
16. Riva CE, Cranstoun SD, Grunwald JE, Petrig BL. Choroidal blood flow in the foveal region of the human ocular fundus. Invest Ophthalmol Vis Sci 1994; 35: 4273-4281.
17. Schlingemann RO. Role of growth factors and the wound healing response in age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 2004; 242: 91-101.
18. Zhu J, Wang YS, Zhang J, Zhao W, Yang XM, Li X et al. Focal adhesion kinase signaling pathway participates in the formation of choroidal neovascularization and regulates the proliferation and migration of choroidal microvascular endothelial cells by acting through HIF-1 and VEGF expression in RPE cells. Exp Eye Res 2009; 88: 910-918.
19. Martin G, Schlunck G, Hansen LL, Agostini HT. Differential expression of angioregulatory factors in normal and CNV-derived human retinal pigment epithelium. Graefes Arch Clin Exp Ophthalmol 2004; 242: 321-326.
20. Zhang P, Zhang X, Hao X, Wang Y, Hui Y, Wang H et al. Rac1 activates HIF-1 in retinal pigment epithelium cells under hypoxia. Graefes Arch Clin Exp Ophthalmol 2009; 247: 633-639.
21. Kvanta A, Algvere PV, Berglin L, Seregard S. Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor. Invest Ophthalmol Vis Sci 1996; 37: 1929-1934.
22. Lopez PF, Sippy BD, Lambert HM, Thach AB, Hinton DR. Transdifferentiated retinal pigment epithelial cells are immunor-eactive for vascular endothelial growth factor in surgically excised age-related macular degeneration-related choroidal neovascular membranes. Invest Ophthalmol Vis Sci 1996; 37: 855-868.
23. Sheridan CM, Pate S, Hiscott P, Wong D, Pattwell DM, Kent D. Expression of hypoxia-inducible factor-1a and-2a in human choroidal neovascular membranes. Graefes Arch Clin Exp Ophthalmol 2009; 247: 1361-1367.
24. Inoue Y, Yanagi Y, Matsuura K, Takahashi H, Tamaki Y, Araie M. Expression of hypoxia-inducible factor 1alpha and 2alpha in choroidal neovascular membranes associated with age-related macular degeneration. Br J Ophthalmol 2007; 91: 1720-1721.
25. 2- regulated gene expression. FASEB J 2002; 16: 1151-1162.
26. Yoshida D, Kim K, Noha M, Teramoto A. Hypoxia inducible factor 1-a regulates of platelet derived growth factor-b in human glioblastoma cells. J Neurooncol 2006; 76: 13-21.
27. Zhao W, Wang YS, Hui YN, Zhu J, Zhang P, Li X et al. Inhibition of proliferation, migration and tube formation of choroidal microvascular endothelial cells by targeting HIF-1alpha with short hairpin RNA-expressing plasmid DNA in human RPE cells in a coculture system. Graefes Arch Clin Exp Ophthalmol 2008; 246: 1413-1422.
28. Zhang P, Wang Y, Hui Y, Hu D, Wang H, Zhou J et al. Inhibition of VEGF expression by targeting HIF-1 alpha with small interference RNA in human RPE cells. Ophthalmologica 2007; 221: 411-417.
29. Campochiaro PA. Potential applications for RNAi to probe pathogenesis and develop new treatments for ocular disorders. Gene Ther 2006; 13: 559-562.
30. Reich SJ, Fosnot J, Kuroki A, Tang W, Yang X, Maguire AM et al. Small interfering RNA (siRNA) targeting VEGF effectively inhibits ocular neovascularization in a mouse model. Mol Vis 2003; 9: 210-216.
31. Tolentino MJ, Brucker AJ, Fosnot J, Ying GS, Wu IH, Malik G et al. Intravitreal injection of vascular endothelial growth factor small interfering RNA inhibits growth and leakage in a nonhuman primate, laser-induced model of choroidal neovas-cularization. Retina 2004; 24: 132-138.
32. Check E. A crucial test. Nat Med 2005; 11: 243-244.
33. Xia XB, Xiong SQ, Xu HZ, Jiang J, Li Y. Suppression of retinal neovascularization by shRNA targeting HIF-1alpha. Curr Eye Res 2008; 33: 892-902.
34. Jain RA, Rhodes CT, Railkar AM, Malick AW, Shah NH. Controlled release of drugs from injectable in situ formed biodegradable PLGA microspheres: effect of various formulation variables. Eur J Pharm Biopharm 2000; 50: 257-262.
35. Hyon SH. Biodegradable poly (lactic acid) microspheres for drug delivery systems. Yonsei Med J 2000; 41: 720-734.
36. Duvvuri S, Janoria KG, Mitra AK. Development of a novel formulation containing poly (D, L-lactide-co-glycolide) micro-spheres dispersed in PLGA-PEG-PLGA Gel for sustained delivery of ganciclovir. J Control Release 2005; 108: 282-293.
37. Hedley ML, Curley J, Urban R. Microspheres containing plasmid-encoded antigens elicit cytotoxic T-cell responses. Nat Med 1998; 4: 365-368.
38. Panyam J, Labhasetwar V. Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv Drug Deliv Rev 2003; 55: 329-347.
39. Giordano GG, Thomson RC, Ishaug SL, Mikos AG, Cumber S, Garcia CA et al. Retinal pigment epithelium cells cultured on synthetic biodegradable polymers. J Biomed Mater Res 1997; 34: 87-93.
40. Kimura H, Ogura Y, Moritera T, Honda Y, Tabata Y, Ikada Y. In vitro phagocytosis of polylactide microspheres by retinal pigment epithelial cells and intracellular drug release. Curr Eye Res 1994; 13: 353-360.
41. Singh SR, Grossniklaus HE, Kang SJ, Edelhauser HF, Ambati BK, Kompella UB. Intravenous transferrin, RGD peptide and dual-targeted nanoparticles enhance anti-VEGF intraceptor gene delivery to laser-induced CNV. Gene Therapy 2009; 16: 645-659.
42. Bejjani RA, BenEzra D, Cohen H, Rieger J, Andrieu C, Jeanny JC et al. Nanoparticles for gene delivery to retinal pigment epithelial cells. Mol Vis 2005; 11: 124-132.
43. Ogura Y, Kimura H. Biodegradable polymer microspheres for targeted drug delivery to the retinal pigment epithelium. Surv Ophthalmol 1995; 39(Suppl 1): S17-S24.
44. Xu J, Wang Y, Li Y, Yang X, Zhang P, Hou H et al. Inhibitory efficacy of intravitreal dexamethasone acetate-loaded PLGA nanoparticles on choroidal neovascularization in a laser-induced rat model. J Ocul Pharmacol Ther 2007; 23: 527-540.
45. Kwak N, Okamoto N, Wood JM, Campochiaro PA. VEGF is major stimulator in model of choroidal neovascularization. Invest Ophthalmol Vis Sci 2000; 41: 3158-3164.
46. Shen J, Samul R, Silva RL, Akiyama H, Liu H, Saishin Y et al. Suppression of ocular neovascularization with siRNA targeting VEGF receptor 1. Gene Therapy 2006; 13: 225-234.
47. Campa C, Kasman I, Ye W, Lee WP, Fuh G, Ferrara N. Effects of an anti-VEGF-A monoclonal antibody on laser-induced chor-oidal neovascularization in mice: optimizing methods to quantify vascular changes. Invest Ophthalmol Vis Sci 2008; 49: 1178-1183.
48. Grunwald JE, Metelitsina TI, Dupont JC, Ying GS, Maguire MG. Reduced foveolar choroidal blood flow in eyes with increasing AMD severity. Invest Ophthalmol Vis Sci 2005; 46: 1033-1038.
49. Grunwald JE, Hariprasad SM, DuPont J, Maguire MG, Fine SL, Brucker AJ et al. Foveolar choroidal blood flow in age-related macular degeneration. Invest Ophthalmol Vis Sci 1998; 39: 385-390.
50. Das A, McGuire PG. Retinal and choroidal angiogenesis: pathophysiology and strategies for inhibition. Prog Retin Eye Res 2003; 22: 721-748.
51. Vinores SA, Xiao WH, Aslam S, Shen J, Oshima Y, Nambu H et al. Implication of the hypoxia response element of the Vegf promoter in mouse models of retinal and choroidal neovascu-larization, but not retinal vascular development. J Cell Physiol 2006; 206: 749-758.
52. Yang XM, Wang YS, Zhang J, Li Y, Xu JF, Zhu J et al. Role of PI3K/Akt and MEK/ERK in mediating hypoxia-induced expression of HIF-1\{Alpha\} and VEGF in laser-induced rat choroidal neovascularization. Invest Ophthalmol Vis Sci 2009; 50: 1873-1879.
53. Semenza GL, Wang GL. A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. Mol Cell Biol 1992; 12: 5447-5454.
54. Guerrin M, Moukadiri H, Chollet P, Moro F, Dutt K, Malecaze F et al. Vasculotropin/vascular endothelial growth factor is an autocrine growth factor for human retinal pigment epithelial cells cultured in vitro. J Cell Physiol 1995; 164: 385-394.
55. Hannon GJ, Rossi JJ. Unlocking the potential of the human genome with RNA interference. Nature 2004; 431: 371-378.
56. Tuschl T, Zamore PD, Lehmann R, Bartel DP, Sharp PA. Targeted mRNA degradation by double-stranded RNA in vitro. Genes Dev 1999; 13: 3191-3197.
57. Caplen NJ, Parrish S, Imani F, Fire A, Morgan RA. Specific inhibition of gene expression by small double-stranded RNAs in invertebrate and vertebrate systems. Proc Natl Acad Sci USA 2001; 98: 9742-9747.
58. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001; 411: 494-498.
59. Sui G, Soohoo C, Affar el B, Gay F, Shi Y, Forrester WC. A DNA vector-based RNAi technology to suppress gene expression in mammalian cells. Proc Natl Acad Sci USA 2002; 99: 5515-5520.
60. Brummelkamp TR, Bernards R, Agami R. A system for stable expression of short interfering RNAs in mammalian cells. Science 2002; 296: 550-553.
61. Yu JY, DeRuiter SL, Turner DL. RNA interference by expression of short-interfering RNAs and hairpin RNAs in mammalian cells. Proc Natl Acad Sci USA 2002; 99: 6047-6052.
62. Cheng TL, Chang WT. Construction of simple and efficient DNA vector-based short hairpin RNA expression systems for specific gene silencing in mammalian cells. Methods Mol Biol 2007; 408: 223-241.
63. Wu MT, Wu RH, Hung CF, Cheng TL, Tsai WH, Chang WT. Simple and efficient DNA vector-based RNAi systems in mammalian cells. Biochem Biophys Res Commun 2005; 330: 53-59.
64. Rao DD, Vorhies JS, Senzer N, Nemunaitis J. Sirna vs. shRNA: similarities and differences. Adv Drug Deliv Rev 2009; 61: 746-759.
65. McAnuff MA, Rettig GR, Rice KG. Potency of siRNA versus shRNA mediated knockdown in vivo. J Pharm Sci 2007; 96: 2922-2930.
66. Wu L, Martinez-Castellanos MA, Quiroz-Mercado H, Arevalo JF, Berrocal MH, Farah ME et al. Twelve-month safety of intravitreal injections of bevacizumab (Avastin): results of the Pan-American Collaborative Retina Study Group (Pacores). Graefes Arch Clin Exp Ophthalmol 2008; 246: 81-87.
67. Bartlett DW, Davis ME. Insights into the kinetics of siRNA-mediated gene silencing from live-cell and live-animal biolumi-nescent imaging. Nucleic Acids Res 2006; 34: 322-333.
68. Maliyekkel A, Davis BM, Roninson IB. Cell cycle arrest drastically extends the duration of gene silencing after transient expression of short hairpin RNA. Cell Cycle 2006; 5: 2390-2395.
69. Panyam J, Zhou WZ, Prabha S, Sahoo SK, Labhasetwar V. Rapid endo-lysosomal escape of poly(D, L-lactide-co-glycolide) nano-particles: implications for drug and gene delivery. FASEB J 2002; 16: 1217-1226.
70. Wattiaux R, Laurent N, Wattiaux-De Coninck S, Jadot M. Endosomes, lysosomes: their implication in gene transfer. Adv Drug Deliv Rev 2000; 41: 201-208.
71. Cohen H, Levy RJ, Gao J, Fishbein I, Kousaev V, Sosnowski S et al. Sustained delivery and expression of DNA encapsulated in polymeric nanoparticles. Gene Ther 2000; 7: 1896-1905.
72. Bourges J-L, Gautier SE, Delie F, Bejjani RA, Jeanny J-C, Gurny R et al. Ocular drug delivery targeting the retina and retinal pigment epithelium using polylactide nanoparticles. Invest Ophthalmol Vis Sci 2003; 44: 3562-3569.
73. Strauss O. The retinal pigment epithelium in visual function. Physiol Rev 2005; 85: 845-881.
74. Sarks JP, Sarks SH, Killingsworth MC. Morphology of early choroidal neovascularisation in age-related macular degeneration: correlation with activity. Eye 1997; 11: 515-522.
75. Aukunuru JV, Ayalasomayajula SP, Kompella UB. Nanoparticle formulation enhances the delivery and activity of a vascular endothelial growth factor antisense oligonucleotide in human retinal pigment epithelial cells. J Pharm Pharmacol 2003; 55: 1199-1206.
76. Sakurai E, Ozeki H, Kunou N, Ogura Y. Effect of particle size of polymeric nanospheres on intravitreal kinetics. Ophthalmic Res 2001; 33: 31-36.
77. Murata N, Takashima Y, Toyoshima K, Yamamoto M, Okada H. Anti-tumor effects of anti-VEGF siRNA encapsulated with PLGA microspheres in mice. J Control Release 2008; 126: 246-254.
78. Dunne M, Bibby DC, Jones JC, Cudmore S. Encapsulation of protamine sulphate compacted DNA in polylactide and polylac-tide-co-glycolide microparticles. J Control Release 2003; 92: 209-219.
79. Yasukawa T, Hoffmann S, Eichler W, Friedrichs U, Wang YS, Wiedemann P. Inhibition of experimental choroidal neovascu-larization in rats by an alpha(v)-integrin antagonist. Curr Eye Res 2004; 28: 359-366.